Pirinixic acid
Based on 38 publication(s) in Google Scholar
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.34%
- CAS No.: 50892-23-4
- 화학식: C14H14ClN3O2S
- 분자량:323.80
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
HY-15372
GW6471PPARα Antagonist -
HY-10838
GW 501516PPARδ Agonist -
HY-17356
Fenofibrate -
HY-17386
RosiglitazonePPARγ Agonist -
HY-16578
GW9662PPARγ Antagonist -
HY-13861
GW7647PPAR Agonist -
HY-13956
PioglitazonePPARγ Agonist -
HY-50935
TroglitazonePPARγ Agonist -
HY-50202
EtomoxirCPT1a Inhibitor -
HY-13928
GW0742PPAR Agonist -
HY-50108
GW 4064FXR Agonist -
HY-13417
AICARAMPK Activator
Publications Citing Use of MedChemExpress (MCE) Pirinixic acid
More- Cell Metab. 2025 Oct 22:S1550-4131(25)00396-1. [Abstract]
- Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]
- Theranostics. 2021 Jan 1;11(5):2247-2262. [Abstract]
- Theranostics. 2020 Feb 18;10(8):3579-3593. [Abstract]
- J Exp Clin Cancer Res. 2025 Nov 24;45(1):1. [Abstract]
- Adv Sci (Weinh). 2025 Aug 29:e17049. [Abstract]
- Phytomedicine. 2025 Dec 28.
- Phytomedicine. 2025 Sep:145:157045. [Abstract]
- Phytomedicine. 2025 May:140:156598. [Abstract]
- EBioMedicine. 2024 Apr:102:105079. [Abstract]
- J Hazard Mater. 2025 Sep 5:495:139145. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Int J Biol Macromol. 2026 Mar:352:151224. [Abstract]
- Cell Prolif. 2026 Apr 22:e70214. [Abstract]
- Environ Pollut. 2021 Nov 1:288:117792. [Abstract]
- Ecotoxicol Environ Saf. 2022 Feb:231:113173. [Abstract]
- Commun Biol. 2026 Feb 2;9(1):349. [Abstract]
- Mar Drugs. 2025 Nov 24;23(12):450. [Abstract]
- Acta Physiol. 2023 Jun;238(2):e13974. [Abstract]
- Chem Biol Interact. 2026 Jan 25:424:111872. [Abstract]
- Molecules. 2024 Dec 16;29(24):5942. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2026 Apr 1;1872(5):168232. [Abstract]
- Pestic Biochem Physiol. 2025 May:210:106396. [Abstract]
- Cell Signal. 2025 Apr:128:111627. [Abstract]
- J Cell Mol Med. 2022 Feb;26(3):893-912. [Abstract]
- J Inflamm Res. 2022 Aug 22;15:4763-4784. [Abstract]
- iScience. 2023 Nov 14;26(12):108446. [Abstract]
- BMC Cancer. 2019 Dec 2;19(1):1166. [Abstract]
- Cytokine. 2026 May:201:157135. [Abstract]
- Toxicol Appl Pharmacol. 2024 Sep:490:117042. [Abstract]
- Thromb Res. 2024 Jun:238:41-51. [Abstract]
- PPAR Res. 2021 Apr 19:2021:6631605. [Abstract]
- Res Sq. 2026 Jun 5.
- Res Sq. 2026 May 3.
- bioRxiv. 2025 April 10.
- bioRxiv. 2025 January 22.
- Biomed Pharmacother. 2024 Jul:176:116837. [Abstract]
- Heliyon. 2023 Aug 19;9(8):e19150. [Abstract]
Customer Validation & Images
-
RT-PCR
-
IF
-
RT-PCR
-
2D/3D Cell Culture and Differentiation
-
IHC
Biological Activity
제품 설명
IC50 & Target
[1]|
PPARα 0.63 μM (EC50) |
PPARγ 32 μM (EC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| COS-7 | EC50 |
39.8 μM
Compound: 1, WY-14,643
|
Agonist activity at wild-type human PPARalpha LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay
Agonist activity at wild-type human PPARalpha LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay
|
[PMID: 25022880] |
| COS-7 | EC50 |
53.7 μM
Compound: 1
|
Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay
Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay
|
[PMID: 20307981] |
| COS-7 | EC50 |
53.7 μM
Compound: 1, WY-14,643
|
Agonist activity at human PPARgamma LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay
Agonist activity at human PPARgamma LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay
|
[PMID: 25022880] |
| COS-7 | IC50 |
36.3 μM
Compound: 1
|
Activation of human PPARalpha ligand binding domain expressed in COS7 cells by luciferase reporter gene assay
Activation of human PPARalpha ligand binding domain expressed in COS7 cells by luciferase reporter gene assay
|
[PMID: 25037914] |
| COS-7 | IC50 |
53.7 μM
Compound: 1
|
Activation of human PPARgamma ligand binding domain expressed in COS7 cells by luciferase reporter gene assay
Activation of human PPARgamma ligand binding domain expressed in COS7 cells by luciferase reporter gene assay
|
[PMID: 25037914] |
| CV-1 | EC50 |
0.13 μM
Compound: Wy14643
|
Transactivation of human PPARalpha expressed in african green monkey CV1 cells by luciferase reporter gene assay
Transactivation of human PPARalpha expressed in african green monkey CV1 cells by luciferase reporter gene assay
|
[PMID: 22579420] |
| HEK293 | EC50 |
23.33 μM
Compound: WY-14643
|
Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay
Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay
|
[PMID: 23265844] |
| HepG2 | EC50 |
0.04 μM
Compound: WY-14643
|
Agonist activity at mouse PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay
Agonist activity at mouse PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay
|
[PMID: 19053776] |
| HepG2 | EC50 |
1.56 μM
Compound: Wy 14,643
|
Transactivation of GAL4-fused human PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene assay
Transactivation of GAL4-fused human PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene assay
|
[PMID: 23171045] |
| HepG2 | EC50 |
1.56 μM
Compound: Wy-14,643
|
Agonist activity at human GAL4-PPARalpha ligand binding domain expressed in human HepG2 cells by luciferase reporter gene assay
Agonist activity at human GAL4-PPARalpha ligand binding domain expressed in human HepG2 cells by luciferase reporter gene assay
|
[PMID: 25462281] |
| HepG2 | EC50 |
1.6 μM
Compound: Wy-14,643
|
Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay
Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay
|
[PMID: 22341573] |
| HepG2 | EC50 |
1.6 μM
Compound: WY-14643
|
Agonist activity at human PPARgamma ligand binding domain expressed in human HepG2 cells co-transfected with Gal4 by luciferase reporter gene assay
Agonist activity at human PPARgamma ligand binding domain expressed in human HepG2 cells co-transfected with Gal4 by luciferase reporter gene assay
|
[PMID: 18835719] |
| HepG2 | EC50 |
1.6 μM
Compound: WY-14643
|
Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation by luciferase reporter gene assay
Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation by luciferase reporter gene assay
|
[PMID: 19775169] |
| HepG2 | EC50 |
1.6 μM
Compound: WY-14643
|
Agonist activity at human GAL4-fused PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene transactivation assay
Agonist activity at human GAL4-fused PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene transactivation assay
|
[PMID: 22081932] |
| HepG2 | EC50 |
1.6 μM
Compound: WY-14643
|
Effective concentration against human PPARalpha expressed in HepG2 cells
Effective concentration against human PPARalpha expressed in HepG2 cells
|
[PMID: 16107150] |
| HepG2 | EC50 |
1.62 μM
Compound: Wy-14,643
|
Agonist activity at GAL4-DNA binding domain fused human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation incubated for 20 hrs by luciferase reporter gene assay
Agonist activity at GAL4-DNA binding domain fused human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation incubated for 20 hrs by luciferase reporter gene assay
|
[PMID: 25497132] |
| HepG2 | EC50 |
1.62 μM
Compound: WY-14643
|
Agonist activity at human PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay
Agonist activity at human PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay
|
[PMID: 19053776] |
| HepG2 | EC50 |
3.46 μM
Compound: WY14643
|
Agonist activity at GAL4-fused PPARalpha (unknown origin) expressed in human HepG2 cells by transactivation assay
Agonist activity at GAL4-fused PPARalpha (unknown origin) expressed in human HepG2 cells by transactivation assay
|
[PMID: 23502212] |
| HepG2 | EC50 |
4.8 μM
Compound: WY-14643
|
Agonist activity at PPARalpha expressed in human HepG2 cells assessed as induction of receptor transactivation by reporter gene assay relative to control
Agonist activity at PPARalpha expressed in human HepG2 cells assessed as induction of receptor transactivation by reporter gene assay relative to control
|
[PMID: 18625559] |
| HepG2 | EC50 |
4800 nM
Compound: WY-14643
|
Transactivation of human PPARalpha expressed in human HepG2 cells co-transfected with PPRE3-TK-Luc by luciferase reporter gene assay
Transactivation of human PPARalpha expressed in human HepG2 cells co-transfected with PPRE3-TK-Luc by luciferase reporter gene assay
|
[PMID: 21450468] |
| HepG2 | EC50 |
7.1 μM
Compound: WY14643
|
Agonist activity at GAL4-fused PPARalpha A454M mutant (unknown origin) expressed in human HepG2 cells by transactivation assay
Agonist activity at GAL4-fused PPARalpha A454M mutant (unknown origin) expressed in human HepG2 cells by transactivation assay
|
[PMID: 23502212] |
| MCF7 | EC50 |
542 nM
Compound: WY-14643
|
Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay
Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay
|
[PMID: 24936232] |
| MCF7 | EC50 |
650 nM
Compound: WY-14643
|
Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay
Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay
|
[PMID: 24936232] |
| U2OS | EC50 |
12 μM
Compound: WY-14643
|
Agonist activity at human PPARalpha in U2OS cells by transactivation assay
Agonist activity at human PPARalpha in U2OS cells by transactivation assay
|
[PMID: 18329751] |
| U2OS | EC50 |
20 μM
Compound: WY-14643
|
Effect on PPARalpha transactivation activity in U2OS cells
Effect on PPARalpha transactivation activity in U2OS cells
|
[PMID: 16300944] |
In Vitro
Pirinixic acid (Wy-14643) is an agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively[1].
Pirinixic acid (Wy-14643; 0, 10, 100 μM) enhances protein expression of PPAR-α in synovial fibroblasts. Pirinixic acid (0, 10, 100 μM) shows inhibitroy effects on NO and PGE2 production in LPS-stimulated synovial fibroblasts. Pirinixic acid also effectively downregulates expression of inflammatory mediators such as VCAM-1, ICAM-1, ET-1, and TF in synovial fibroblasts, blocks LPS-induced NF-kB activation, IkB phosphorylation, and NF-kB nuclear translocation in synovial fibroblasts, but Pirinixic acid shows no effects in PPAR-α silenced cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 50892-23-4
-
Appearance Solid
-
분자량 323.80
-
화학식 C14H14ClN3O2S
-
Color White to off-white
-
SMILES
O=C(O)CSC1=NC(NC2=CC=CC(C)=C2C)=CC(Cl)=N1
-
Synonyms
Wy-14643
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (38)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα. [Abstract]2025 Oct 22:S1550-4131(25)00396-1. PMID: 41130202 -
Cell Stem Cell
Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal. [Abstract]2022 Sep 1;29(9):1366-1381.e9. PMID: 36055192
Pirinixic acid purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]
Crypts isolated from Lgr5-EGFP-IRES-creERT2 mice were cultured with CA together with/without 100 μM WY14643/ 10 μM Pioglitazone/ 1 μM GW501516 for 6 days. Representative staining pattern of Lgr5+ cells.
Pirinixic acid purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]
Crypts isolated from Lgr5-EGFP-IRES-creERT2 mice were cultured with 50 μM CA together with/without 100 μM WY14643 for 6 days. The mRNA level of a specified gene.
Pirinixic acid purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]
Crypts isolated from Lgr5-EGFP-IRES-creERT2 mice were cultured with 50 μM CA together with/without 100 μM for 6 days. Representative images analysis of organoid budding.
Pirinixic acid purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]
WY14643 (1 mg/kg; i.g.). Colitic WT mice were administered with vehicle or WY14643. Representative H&E staining images of intestinal segments.
-
Theranostics
Activation of N-methyl-D-aspartate receptor regulates insulin sensitivity and lipid metabolism. [Abstract]2021 Jan 1;11(5):2247-2262. PMID: 33500723 -
Theranostics
NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease. [Abstract]2020 Feb 18;10(8):3579-3593. PMID: 32206109 -
J Exp Clin Cancer Res
GSTK1 suppresses HCC aggravation via L-carnitine metabolism by PGAM5/DRP1 complex-mediated mitochondrial quality control. [Abstract]2025 Nov 24;45(1):1. PMID: 41276823 -
Adv Sci (Weinh)
Reprogramming of Fatty Acid Metabolism via PPARα-Orchestrated FADS2 in Keratinocytes Modulates Skin Inflammation in Psoriasis. [Abstract]2025 Aug 29:e17049. PMID: 40878384
Pirinixic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 29:e17049. [Abstract]
RT-qPCR analysis of FADS2 and indicated genes in HaCaT cells pretreated with 50 μM WY14643 or DMSO for 21 h, followed by PBS or M5 stimulation for 3 h.
-
-
Phytomedicine
Calycosin alleviates myocardial fibrosis after myocardial infarction by restoring fatty acid metabolism homeostasis through inhibiting FAP. [Abstract]2025 Sep:145:157045. PMID: 40627929 -
Phytomedicine
Poncirin ameliorates alcoholic liver injury by regulating lipid metabolism and inflammatory response in a PPARα dependent manner. [Abstract]2025 May:140:156598. PMID: 40056635 -
EBioMedicine
Peripheral amyloid-β clearance mediates cognitive impairment in non-alcoholic fatty liver disease. [Abstract]2024 Apr:102:105079. PMID: 38507874 -
J Hazard Mater
Long-term low-dose exposure to 9-chlorophenanthrene induces liver lipid accumulation via disrupting circadian rhythm. [Abstract]2025 Sep 5:495:139145. PMID: 40628211 -
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Int J Biol Macromol
Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]2026 Mar:352:151224. PMID: 41791543 -
Cell Prolif
Targeting Egfr-Mediated Cell Proliferation and Lipid Metabolism Separation Effectively Accelerate Liver Regeneration. [Abstract]2026 Apr 22:e70214. PMID: 42019507 -
Environ Pollut
Mitochondria damage in ambient particulate matter induced cardiotoxicity: Roles of PPAR alpha/PGC-1 alpha signaling. [Abstract]2021 Nov 1:288:117792. PMID: 34280742 -
Ecotoxicol Environ Saf
Real ambient particulate matter-induced lipid metabolism disorder: Roles of peroxisome proliferators-activated receptor alpha. [Abstract]2022 Feb:231:113173. PMID: 35007830 -
Commun Biol
2026 Feb 2;9(1):349. PMID: 41629390 -
Mar Drugs
Novel PPAR-γ Agonist from the Soft Coral Sarcophyton crassocaule: Modulating Glucose Uptake and Lipid Droplet Formation. [Abstract]2025 Nov 24;23(12):450. PMID: 41440884 -
Acta Physiol
SARM1 promotes the neuroinflammation and demyelination through IGFBP2/NF-κB pathway in experimental autoimmune encephalomyelitis mice. [Abstract]2023 Jun;238(2):e13974. PMID: 37186158 -
Chem Biol Interact
New insights into Lambda-cyhalothrin-induced lipid metabolism disorder in liver: Crosstalk between oxidative stress and PPARα signaling pathway. [Abstract]2026 Jan 25:424:111872. PMID: 41386472 -
Molecules
Identification of New Polyacetylenes from Dendropanax morbifera with PPAR-α Activity Study. [Abstract]2024 Dec 16;29(24):5942. PMID: 39770031 -
Biochim Biophys Acta Mol Basis Dis
USP47 alleviates metabolic-associated fatty liver disease by activating the PPARα signaling pathway through the stabilization of SIRT1. [Abstract]2026 Apr 1;1872(5):168232. PMID: 41930505 -
Pestic Biochem Physiol
Polystyrene-microplastics and Emamectin Benzoate co-exposure induced lipid remodeling by suppressing PPARα signals to drive ACSL4-dependent ferroptosis and carp splenic injury. [Abstract]2025 May:210:106396. PMID: 40262874 -
Cell Signal
HDAC2 promotes colorectal tumorigenesis by triggering dysregulation of lipid metabolism through YAP1. [Abstract]2025 Apr:128:111627. PMID: 39875048 -
J Cell Mol Med
Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy. [Abstract]2022 Feb;26(3):893-912. PMID: 34964241 -
J Inflamm Res
The Key Molecular Mechanisms of Sini Decoction Plus Ginseng Soup to Rescue Acute Liver Failure: Regulating PPARα to Reduce Hepatocyte Necroptosis?. [Abstract]2022 Aug 22;15:4763-4784. PMID: 36032938 -
iScience
Mof plays distinct roles in hepatic lipid metabolism under healthy or non-alcoholic fatty liver conditions. [Abstract]2023 Nov 14;26(12):108446. PMID: 38034359 -
BMC Cancer
PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis. [Abstract]2019 Dec 2;19(1):1166. PMID: 31791289 -
Cytokine
The LA-NF-κB-ILC2 axis exacerbates intestinal milk protein allergy in mice by promoting ILC2 activation. [Abstract]2026 May:201:157135. PMID: 41780286 -
Toxicol Appl Pharmacol
Liquidambaric acid inhibits the proliferation of hepatocellular carcinoma cells by targeting PPARα-RXRα to down-regulate fatty acid metabolism. [Abstract]2024 Sep:490:117042. PMID: 39067772 -
Thromb Res
2024 Jun:238:41-51. PMID: 38669962 -
PPAR Res
Hydroxychloroquine Potentiates Apoptosis Induced by PPAR α Antagonist in 786-O Clear Cell Renal Cell Carcinoma Cells Associated with Inhibiting Autophagy. [Abstract]2021 Apr 19:2021:6631605. PMID: 33959154 -
-
-
-
-
Biomed Pharmacother
PIEZO1 as a new target for hyperglycemic stress-induced neuropathic injury: The potential therapeutic role of bezafibrate. [Abstract]2024 Jul:176:116837. PMID: 38815290 -
Heliyon
Air-ventilated normothermic machine perfusion alleviates hepatic injury from DCD rat through CYP1A2. [Abstract]2023 Aug 19;9(8):e19150. PMID: 37654459
용액&용해도
In Vitro:
DMSO : 100 mg/mL (308.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 10 mg/mL (30.88 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 10 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.42 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (286 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43(4):527-50. [Content Brief]
[2]. Huang D, et al. PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway. J Mol Neurosci. 2016 Aug;59(4):544-53. [Content Brief]
[3]. Pantazi E, et al. PPARα Agonist WY-14643 Induces SIRT1 Activity in Rat Fatty Liver Ischemia-Reperfusion Injury. Biomed Res Int. 2015;2015:894679. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0883 mL | 15.4416 mL | 30.8833 mL | 77.2082 mL |
| 5 mM | 0.6177 mL | 3.0883 mL | 6.1767 mL | 15.4416 mL | |
| 10 mM | 0.3088 mL | 1.5442 mL | 3.0883 mL | 7.7208 mL | |
| 15 mM | 0.2059 mL | 1.0294 mL | 2.0589 mL | 5.1472 mL | |
| 20 mM | 0.1544 mL | 0.7721 mL | 1.5442 mL | 3.8604 mL | |
| 25 mM | 0.1235 mL | 0.6177 mL | 1.2353 mL | 3.0883 mL | |
| 30 mM | 0.1029 mL | 0.5147 mL | 1.0294 mL | 2.5736 mL | |
| 40 mM | 0.0772 mL | 0.3860 mL | 0.7721 mL | 1.9302 mL | |
| 50 mM | 0.0618 mL | 0.3088 mL | 0.6177 mL | 1.5442 mL | |
| 60 mM | 0.0515 mL | 0.2574 mL | 0.5147 mL | 1.2868 mL | |
| 80 mM | 0.0386 mL | 0.1930 mL | 0.3860 mL | 0.9651 mL | |
| 100 mM | 0.0309 mL | 0.1544 mL | 0.3088 mL | 0.7721 mL |
Pirinixic acid Related Classifications
HY-16995 Related Classifications
Powered by Bioz